Biohope Secures Near-Maximum Funding in Madrid’s 2023 Call for Innovative SMEs
Madrid, September 2024 — Biohope, a pioneering biotech company, has been awarded €248,714.34 in funding under the 2023 call for support to innovative small and medium-sized enterprises (SMEs) by the Community of Madrid. This amount is just shy of the maximum possible grant of €250,000, highlighting the project’s strong evaluation and strategic relevance.
The funding falls under Line 3: Innovative SMEs with more than five years of activity, aimed at boosting mature companies with a proven track record in innovation.
Biohope’s project, titled “Evaluation, for functional cell testing, of the stability and quality of peripheral blood mononuclear cells (PBMCs) over time,” will officially commence in September 2024. The initiative is expected to conclude by the end of the first quarter of 2026.
This research aims to enhance the reliability and performance of PBMCs in functional assays, which are critical for immunological diagnostics and therapeutic monitoring. The project aligns with Biohope’s mission to advance personalized medicine through robust immunological tools.
With this support, Biohope continues to strengthen its position as a leader in immunology-focused innovation, contributing to the development of cutting-edge solutions for transplant medicine and beyond.
